Sax on HIV/AIDS

• Long-acting Injectable Cabotegravir for PrEP Is Promising   Dr Paul Sax discusses the interim results from a study on the use of the long-acting injectable cabotegravir for pre-exposure prophylaxis in cisgender men and transgender women who have sex with men.
  Medscape HIV/AIDS, June 23, 2020
• COVID-19 in People With HIV: Commonly Asked Questions   Dr Paul Sax gives answers to some of the most commonly asked questions he has received from patients with HIV.
  Medscape HIV/AIDS, April 03, 2020
• Low-Level Viremia in HIV: When Should We Worry?   Is all low-level viremia in HIV the same, and does it lead to virologic failure? Dr Sax comments on a new study.
  Medscape HIV/AIDS, March 11, 2020
• Time to Rethink Renal Dosing of Lamivudine?   Dose reductions of lamivudine may not be necessary for all patients with mild to moderate renal impairment, says Dr Paul Sax.
  Medscape HIV/AIDS, November 18, 2019
• Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?   CCR5- delta 32 mutation homozygosity is associated with increased mortality but may lead to a potential cure for HIV. Is it worth the risk?
  Medscape HIV/AIDS, July 19, 2019
• PrEP and Risk for Sexually Transmitted Infections   Dr Paul Sax shares what he thinks is most interesting and useful about the findings that STI risk is elevated in PrEP users.
  Medscape HIV/AIDS, May 03, 2019
• Why ID Doctors Might Be Less Happy   Happy ID doc Paul Sax comments on the results of a Medscape survey about happiness among ID physicians.
  Medscape HIV/AIDS, February 21, 2019
• Two- vs Three-Drug Initial Therapy for HIV   Dr Paul Sax describes the potential clinical implications of the GEMINI studies.
  Medscape HIV/AIDS, November 26, 2018
• A Precaution About PrEP in HIV Prevention   PrEP can reduce new HIV infections if taken as directed. So why do PrEP failures occur?
  Medscape HIV/AIDS, November 12, 2018
• What Doravirine Offers Patients With HIV   Dr Paul Sax describes the trials that led to the approval of doravirine, which might offer some benefits to patients who can't tolerate other NNRTIs.
  Medscape HIV/AIDS, September 13, 2018
• The New Single-Tablet HIV Drug: How We Might Use It   Dr Paul Sax comments on the place Symtuza? might occupy in the HIV treatment 'medicine chest.'
  Medscape HIV/AIDS, August 02, 2018
• Here's What's New in the HIV Treatment Guidelines   Dr Paul Sax reports on a new recommended HIV treatment option and thanks Marty Hirsch for his skillful leadership of the guidelines working group.
  Medscape HIV/AIDS, April 20, 2018
• This Novel, 1-Month Regimen to Prevent TB Is Practice-Changing   Dr Paul Sax reports on an intriguing two-drug regimen that could become the standard of care in preventing TB.
  Medscape HIV/AIDS, March 26, 2018
• The SWORD Study: A New Two-Drug Combo for HIV   Dr Paul Sax highlights the findings of the SWORD study of dolutegravir-rilpivirine and outlines the clinical implications.
  Medscape HIV/AIDS, March 01, 2018
• Why Quarantine 'Makes No Sense' in Controlling HIV   Controversy spurred by comments from Georgia state representative Dr Betty Price on HIV is addressed by Dr Paul Sax.
  Medscape HIV/AIDS, October 30, 2017
• Early HIV Therapy and Remission: 'Both Sides of the Coin'   Dr Paul Sax discusses very early antiretroviral therapy in two cases presented at IAS 2017, in which one patient remains in remission and the other does not.
  Medscape HIV/AIDS, August 11, 2017
• The Top 5 Stories in HIV Medicine for 2016   Dr Sax reveals his picks for the top 5 stories in HIV medicine, including the approval of drug combinations and gains made in the search for a cure.
  Medscape HIV/AIDS, January 20, 2017
• 'Same-Day' ART Initiation: Better Retention in Care, Outcomes   Initiating ART on the same day as HIV diagnosis led to better retention in care and patient outcomes in a trial in Haiti.
  Medscape HIV/AIDS, September 21, 2016
• International Aids Conference: Novel Studies Compare ART Regimens   Dr Paul Sax discusses the latest findings from the ARIA, REALITY, and PADDLE trials.
  Medscape HIV/AIDS, August 26, 2016
• TAF/FTC Approved: Benefits and Limitations in Clinical Practice   Dr Paul Sax talks about the recent FDA approval of the third tenofovir alafenamide coformulation for the treatment of HIV, and discusses circumstances in which it should be used with caution.
  Medscape HIV/AIDS, May 20, 2016